Prostaglandin I2 analog suppresses lung metastasis by recruiting pericytes in tumor angiogenesis

Minami,Yoshinori; Sasaki,Takaaki; Bochimoto,Hiroki; Kawabe,Jun‑Ichi; Endo,Satoshi; Hira,Yoshiki; Watanabe,Tsuyoshi; Okumura,Shunsuke; Hasebe,Naoyuki; Ohsaki,Yoshinobu

doi:10.3892/ijo.2014.2783

Prostaglandin I2 analog suppresses lung metastasis by recruiting pericytes in tumor angiogenesis

Authors:
- Yoshinori Minami
- Takaaki Sasaki
- Hiroki Bochimoto
- Jun‑Ichi Kawabe
- Satoshi Endo
- Yoshiki Hira
- Tsuyoshi Watanabe
- Shunsuke Okumura
- Naoyuki Hasebe
- Yoshinobu Ohsaki
View Affiliations

Affiliations: Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan, Department of Microscopic Anatomy and Cell Biology, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan, Department of Cardiovascular Regeneration and Innovation, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan, Cardiovascular, Respiratory and Neurology Division, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido 078‑8510, Japan
Published online on: November 28, 2014 https://doi.org/10.3892/ijo.2014.2783
Pages: 548-554

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostaglandin I2 (PGI2) agonist has been reported to reduce tumor metastasis by modifying tumor angiogenesis; however, the mechanisms of how PGI2 affects the endothelial cells or pericytes in tumor vessel maturation are still unclear. The purpose of this study was to clarify the effects of PGI2 on tumor metastasis in a mouse lung metastasis model using Lewis lung carcinoma (LLC) cells. The mice were treated continuously with beraprost sodium (BPS), a PGI2 analog, for 3 weeks and then examined for lung metastases. The number and size of lung metastases were decreased significantly by BPS treatment. In addition, scanning electron microscopy and immunohistochemistry revealed that BPS increased the number of tumor‑associated pericytes and improved intratumor hypoxia. Collectively, this study suggests that BPS attenuated vascular functional maturation in metastatic tumors.

View Figures

View References

1	Turner EC, Mulvaney EP, Reid HM and Kinsella BT: Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis. Mol Biol Cell. 22:2664–2679. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zhu W, Saddar S, Seetharam D, et al: The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res. 102:480–487. 2008. View Article : Google Scholar : PubMed/NCBI
3	Honn KV, Cicone B and Skoff A: Prostacyclin: a potent antimetastatic agent. Science. 212:1270–1272. 1981. View Article : Google Scholar : PubMed/NCBI
4	Gorelik E, Bere WW and Herberman RB: Role of NK cells in the antimetastatic effect of anticoagulant drugs. Int J Cancer. 33:87–94. 1984. View Article : Google Scholar : PubMed/NCBI
5	Menter DG, Harkins C, Onoda J, et al: Inhibition of tumor cell induced platelet aggregation by prostacyclin and carbacyclin: an ultrastructural study. Invasion Metastasis. 7:109–128. 1987.PubMed/NCBI
6	Niitsu Y, Ishigaki S, Kogawa K, et al: Effect of combined administration of a prostacyclin analogue and adriamycin against the artificial metastasis of Meth A cell. Invasion Metastasis. 8:57–72. 1988.PubMed/NCBI
7	Sava G, Perissin L, Zorzet S, Piccini P and Giraldi T: Antimetastatic action of the prostacyclin analog iloprost in the mouse. Clin Exp Metastasis. 7:671–678. 1989. View Article : Google Scholar : PubMed/NCBI
8	Honn KV: Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis. 1:103–114. 1983. View Article : Google Scholar : PubMed/NCBI
9	Karpatkin S, Ambrogio C and Pearlstein E: Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells. Cancer Res. 44:3880–3883. 1984.PubMed/NCBI
10	Mahalingam M, Ugen KE, Kao KJ and Klein PA: Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants. Cancer Res. 48:1460–1464. 1988.PubMed/NCBI
11	Lapis K, Timár J, Pápay J, Paku S, Szende B and Ladányi A: Experimental metastasis inhibition by pretreatment of the host. Arch Geschwulstforsch. 60:97–102. 1990.PubMed/NCBI
12	Kato S, Kobari M, Matsuno S and Sato T: Inhibitory effect of anti-platelet prostaglandin on liver metastasis of hamster pancreatic cancer. Nihon Geka Gakkai Zasshi. 90:745–752. 1989.(In Japanese). PubMed/NCBI
13	Schwalke MA, Tzanakakis GN and Vezeridis MP: Effects of prostacyclin on hepatic metastases from human pancreatic cancer in the nude mouse. J Surg Res. 49:164–167. 1990. View Article : Google Scholar : PubMed/NCBI
14	Tzanakakis GN, Agarwal KC and Vezeridis MP: Inhibition of hepatic metastasis from a human pancreatic adenocarcinoma (RWP-2) in the nude mouse by prostacyclin, forskolin, and ketoconazole. Cancer. 65:446–451. 1990. View Article : Google Scholar : PubMed/NCBI
15	Costantini V, Fuschiotti P, Giampietri A, et al: Effects of a stable prostacyclin analogue on platelet activity and on host immunocompetence in mice. Prostaglandins. 39:581–599. 1990. View Article : Google Scholar : PubMed/NCBI
16	Pasqualini R, Arap W and McDonald DM: Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med. 8:563–571. 2002. View Article : Google Scholar : PubMed/NCBI
17	Minami Y, Sasaki T, Kawabe J and Ohsaki Y: Accessory cells in tumor angiogenesis - tumor-associated pericytes. Research Directions in Tumor Angiogenesis. Chai J: InTech; Croatia: pp. 73–89. 2013
18	Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK and McDonald DM: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 160:985–1000. 2002. View Article : Google Scholar : PubMed/NCBI
19	O’Keeffe MB, Devlin AH, Burns AJ, et al: Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol Res. 17:93–101. 2008.
20	Stefansson IM, Salvesen HB and Akslen LA: Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Res. 66:3303–3309. 2006. View Article : Google Scholar : PubMed/NCBI
21	Yonenaga Y, Mori A, Onodera H, et al: Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology. 69:159–166. 2005. View Article : Google Scholar : PubMed/NCBI
22	Xian X, Håkansson J, Ståhlberg A, et al: Pericytes limit tumor cell metastasis. J Clin Invest. 116:642–651. 2006. View Article : Google Scholar : PubMed/NCBI
23	Kawabe J, Yuhki K, Okada M, et al: Prostaglandin I₂ promotes recruitment of endothelial progenitor cells and limits vascular remodeling. Arterioscler Thromb Vasc Biol. 30:464–470. 2010. View Article : Google Scholar
24	Ushiki T and Murakumo M: Scanning electron microscopic studies of tissue elastin components exposed by a KOH-collagenase or simple KOH digestion method. Arch Histol Cytol. 54:427–436. 1991. View Article : Google Scholar : PubMed/NCBI
25	Tennis MA, Van Scoyk M, Heasley LE, et al: Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1. Neoplasia. 12:244–253. 2010.PubMed/NCBI
26	Honn KV and Meyer J: Thromboxanes and prostacyclin: positive and negative modulators of tumor growth. Biochem Biophys Res Commun. 102:1122–1129. 1981. View Article : Google Scholar : PubMed/NCBI
27	Tang DG, Grossi IM, Chen YQ, Diglio CA and Honn KV: 12(S)-HETE promotes tumor-cell adhesion by increasing surface expression of alpha V beta 3 integrins on endothelial cells. Int J Cancer. 54:102–111. 1993. View Article : Google Scholar : PubMed/NCBI
28	Honn KV, Busse WD and Sloane BF: Prostacyclin and thromboxanes. Implications for their role in tumor cell metastasis. Biochem Pharmacol. 32:1–11. 1983. View Article : Google Scholar : PubMed/NCBI
29	Menter DG, Onoda JM, Moilanen D, Sloane BF, Taylor JD and Honn KV: Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation. J Natl Cancer Inst. 78:961–969. 1987.PubMed/NCBI
30	Menter DG, Onoda JM, Taylor JD and Honn KV: Effects of prostacyclin on tumor cell-induced platelet aggregation. Cancer Res. 44:450–456. 1984.PubMed/NCBI
31	Honn KV, Tang DG, Grossi IM, et al: Enhanced endothelial cell retraction mediated by 12(S)-HETE: a proposed mechanism for the role of platelets in tumor cell metastasis. Exp Cell Res. 210:1–9. 1994. View Article : Google Scholar : PubMed/NCBI
32	Honn KV, Grossi IM, Diglio CA, Wojtukiewicz M and Taylor JD: Enhanced tumor cell adhesion to the subendothelial matrix resulting from 12(S)-HETE-induced endothelial cell retraction. FASEB J. 3:2285–2293. 1989.PubMed/NCBI
33	Honn KV, Tang DG, Grossi I, et al: Tumor cell-derived 12(S)-hydroxyeicosatetraenoic acid induces microvascular endothelial cell retraction. Cancer Res. 54:565–574. 1994.PubMed/NCBI
34	Aburakawa Y, Kawabe J, Okada M, et al: Prostacyclin stimulated integrin-dependent angiogenic effects of endothelial progenitor cells and mediated potent circulation recovery in ischemic hind limb model. Circ J. 77:1053–1062. 2013. View Article : Google Scholar
35	Cipriani P, Marrelli A, Benedetto PD, et al: Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis. 16:595–607. 2013. View Article : Google Scholar : PubMed/NCBI